Simplify and scale
your gene therapy manufacturing
From development to scale: robust, reproducible,
and high-quality AAV production
Fill out the form to connect with a cell line specialist
Stable, inducible AAV production designed for scalable manufacturing
Say hello to ELEVECTA™ stable producer cell line 2.0
A re-engineered HEK293-based cell line designed for controlled, on-demand AAV production, ELEVECTA™ stable producer cell line 2.0 gives you precise control over vector expression. Built with CMC-driven development in mind, it enables predictable performance, simplified process validation, and consistent output across scales.
Integrated genes for streamlined production
ELEVECTA™ stable producer cell line 2.0 integrates Rep, Helper, Cap, and GOI directly into the genome eliminating the need for plasmids or helper virus.
- Single-step Cap + GOI integration accelerates pool generation
- Optimized constructs improve titer and packaging efficiency
- Strong performance achieved at the polyclonal pool stage
Lower encapsidated hcDNA for enhanced quality confidence
Genetic engineering of ELEVECTA™ stable producer cell line 2.0 reduces encapsidated host‑cell DNA – an impurity that cannot be effectively cleared downstream – helping strengthen quality, reduce risk during development and scale-up, and aligning with regulatory expectations.
Key advantages of ELEVECTA™ stable producer cell line 2.0
- Simplified manufacturing workflow: Single‑step induction replaces complex transfection – just add induction reagent to start production, cutting complexity and timelines.
- Scalable from bench to production: Consistent, high‑quality AAV output from bench scale through large‑scale manufacturing.
- Enhanced reproducibility: Reliable, batch‑to‑batch AAV production with documented lineage.
- Lower cost of goods: Eliminates plasmids and transfection reagents while simplifying operations to reduce manufacturing costs.
